multiple myeloma
Conditions
Interventions
Experimental group:VRD protocol (Bortezomib, Lenadomide, Dexamethasone) + RIF
Control group:VRD protocol (Bortezomib, Lenadomide, Dexamethasone)
Sponsors
Huadong Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. sign the informed consent; 2. patient with multiple myeloma, aged 18-80 years old, ECOG score 40%, no arrhythmia or heart rhythm instability, serum bilirubin < 2×normal limit, serum Alt < 4×normal limit, no chronic active hepatitis or cirrhosis of the liver, kidney function in CKD4 stage below, pregnancy test negative, for women with reproductive potential, consent of herself and family members.
Exclusion criteria
Exclusion criteria: 1) grade 4 hematological adverse reaction occurred during the treatment; 2) during the treatment, LV auxiliary device, intra-aortic balloon pump (IABP) or any type of detection means are used to detect end-stage heart failure, and coronary artery revascularization, electrophysiological device implantation, cardiac mechanical support implantation or other cardiac surgery are required due to the condition; 3) serious illness or with shorter life expectancy, make plan or difficult to explain the results of the study (cardiovascular disease (including New York heart association class for IV, congestive heart failure), respiratory, liver and nervous system, including treatment in stroke psychiatry or active malignancy (except the melanoma skin cancer is not out of scope or other major systemic disease; 4) any actual or expected other conditions (such as regional and social) that the researcher believes may limit the patient's participation during the study period; 5) specific regulations of any country that prevent patients from entering the study (e.g., restricted by judicial rulings or administrative orders); 6) during the study and follow-up, women of reproductive age were unwilling to take effective contraceptive measures or were unwilling or unable to receive pregnancy tests during the study; 7) disease developing during follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| M protein; | — |
Countries
China
Contacts
Public ContactChen Pingping
Huadong Hospital
Outcome results
None listed